News

December 4, 2018

Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders.

Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases.

Strasbourg, France, December 4, 2018 – Domain Therapeutics announces a multi-target…

Continue Reading
August 23, 2018

In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment for Major Depressive Disorder

Jean M. Bidblack, Brian I. Knapp, Daniel R. Deaver, Margarita Plotnikava, Derrick Arnelle, Angela M. Wonsey, May Fern Toh, Sokhom S. Pin, and Mark N. Namchuk

Continue Reading

March 5, 2018

Domain Therapeutics octroie à Bristol-Myers Squibb une licence non exclusive sur la technologie bioSens-All™ dédiée aux récepteurs couplés aux protéines G

La technologie donne accès à une nouvelle génération de biosenseurs visant à optimiser la découverte de médicaments

Strasbourg, France, le 27 février 2018 – Domain Therapeutics, une société biopharmaceutique…

Continue Reading
March 5, 2018

Domain Therapeutics grants Bristol-Myers Squibb non-exclusive license for G protein-coupled receptor bioSens-All™ technology

Technology provides access to new generation of sensitive biosensors to enhance drug discovery

Strasbourg, France, February 27, 2018 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the…

Continue Reading
May 5, 2017

Pfizer Inc. and Domain Therapeutics enter into a collaboration agreement on bioSensAll™

Proprietary technology will be used to profile signaling of mutant GPCRs in order to improve and accelerate the validation of novel GPCR drug targets

Strasbourg, France, and Montreal,…

Continue Reading
December 14, 2016

DT signs GPCR licensing agreement with Alkermes.

Domain Therapeutics grants Alkermes a non-exclusive license for its G Protein-Coupled Receptor bioSensAll™ technology. Technology provides access to a new set of sensitive biosensors that will facilitate drug…

Continue Reading
September 27, 2016

DT, Université de Montréal, IRICoR and McGill University extend licensing and partnership agreement on G Protein-Coupled Receptor biosensor technology.

Domain Therapeutics will get exclusive access to a new set of more powerful biosensors that will facilitate profiling of more effective and safer drug candidates.

Domain Therapeutics, a France…

Continue Reading
January 20, 2014

DT opens a North American subsidiary at Montreal’s NEOMED Institute.

Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All(TM) technology.

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting…

Continue Reading
December 18, 2013

DT, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.

Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased to announce the…

Continue Reading